Early changes in biochemical markers of bone formation during teriparatide therapy correlate with improvements in vertebral strength in men with glucocorticoid-induced osteoporosis

Osteoporosis International

Volumn 24, Issue 12, 2013, Pages 2971-2981

  Farahmand, P ^a   Marin, F ^b   Hawkins, F ^c   Moricke R ^d   Ringe, J D ^a   Gluer C C ^e   Papaioannou, N ^f   Minisola, S ^g   Martinez G ^c   Nolla, J M ^h   Niedhart, C ⁱ   Guanabens N ^j   Nuti, R ^k   Martin Mola E ^l   Thomasius, F ^m   Pena J ^e   Graeff, C ^e   Kapetanos, G ⁿ   Petto, H ^o   Gentzel, A ^b   Reisinger, A ^p   Zysset, P K ^q   more..

^a UNIVERSITY OF COLOGNE   (Germany)

^b ELI LILLY AND COMPANY   (United States)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d Institut Präventive Medizin Klinische Forschung   (Germany)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^g POLICLINICO UMBERTO I   (Italy)

^h HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

ⁱ Gemeinschaftspraxis   (Germany)

^j HOSPITAL CLÍNIC   (Spain)

^k UNIVERSITY HOSPITAL OF SIENA   (Italy)

^l HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^m Osteoporose Studiengesellschaft bR   (Germany)

ⁿ ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^o Lilly Research Laboratories   (Austria)

^p VIENNA UNIVERSITY OF TECHNOLOGY   (Austria)

^q Institute for Surgical Technology and Biomechanics   (Switzerland)

more..

Author keywords

Biochemical markers of bone turnover; bone strength; finite element analysis; glucocorticoid induced osteoporosis; male osteoporosis; teriparatide

Indexed keywords

25 HYDROXYVITAMIN D; ALKALINE PHOSPHATASE; BIOLOGICAL MARKER; CALCIUM; PARATHYROID HORMONE[1-34]; PINP PROTEIN; RISEDRONIC ACID; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BONE STRENGTH; BONE TURNOVER; CALCIUM BLOOD LEVEL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE MARKER; FEMALE; FINITE ELEMENT ANALYSIS; FOLLOW UP; GLUCOCORTICOID INDUCED OSTEOPOROSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; OSSIFICATION; OSTEOPOROSIS; PRIORITY JOURNAL; SPINE FRACTURE; VERTEBRA;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BIOMECHANICAL PHENOMENA; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; ETIDRONIC ACID; FEMUR NECK; FINITE ELEMENT ANALYSIS; GLUCOCORTICOIDS; HUMANS; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; OSTEOGENESIS; OSTEOPOROSIS; PEPTIDE FRAGMENTS; PROCOLLAGEN; TERIPARATIDE; TREATMENT OUTCOME;

EID: 84890431312     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-013-2379-5     Document Type: Article

References (57)

1. Vasikaran S, Eastell R, Bruyère O, Foldes AJ, Garnero P, Griesmacher A, McClung M, Morris HA, Silverman S, Trenti T, Wahl DA, Cooper C, Kanis JA, IOF-IFCC Bone Marker Standards Working Group (2011) Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 22:391-420
2. Szulc P (2012) The role of bone turnover markers in monitoring treatment in postmenopausal osteoporosis. Clin Biochem 45:907-919
3. Ravn P, Clemmesen B, Christiansen C (1999) Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group. Bone 24:237-244
4. Lane NE, Sanchez S, Genant HK, Jenkins DK, Arnaud CD (2000) Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporos Int 11:434-442
5. Bjarnason NH, Sarkar S, Duong T, Mitlak B, Delmas PD, Christiansen C (2001) Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 12:922-930
6. Reginster JY, Sarkar S, Zegels B, Henrotin Y, Bruyere O, Agnusdei D, Collette J (2004) Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk. Bone 34:344-351
7. Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, Thompson DE, Ewing SK, Delmas PD; Fracture Intervention Trial Study Group (2004) Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the Fracture Intervention Trial. J Bone Miner Res 19:1250-1258
8. Sarkar S, Reginster JY, Crans GG, Diez-Perez A, Pinette KV, Delmas PD (2004) Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res 19:394-401
9. Chen P, Satterwhite JH, Licata AA, Lewiecki EM, Sipos AA, Misurski DM, Wagman RB (2005) Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 20:962-970
10. Dobnig H, Sipos A, Jiang Y, Fahrleitner-Pammer A, Ste-Marie LG, Gallagher JC, Pavo I, Wang J, Eriksen EF (2005) Early changes in biochemical markers of bone formation correlate with improvements in bone structure during teriparatide therapy. J Clin Endocrinol Metab 90:3970-3977
11. Greenspan SL, Resnick NM, Parker RA (2005) Early changes in biochemical markers of bone turnover are associated with long-term changes in bone mineral density in elderly women on alendronate, hormone replacement therapy, or combination therapy: a three-year, double-blind, placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab 90:2762-2767
12. Bauer DC, Garnero P, Bilezikian JP, Greenspan SL, Ensrud KE, Rosen CJ, Palermo L, Black DM (2006) Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 91:1370-1375
13. Finkelstein JS, Leder BZ, Burnett SM, Wyland JJ, Lee H, de la Paz AV, Gibson K, Neer RM (2006) Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men. J Clin Endocrinol Metab 91:2882-2887
14. Jacobs JW, de Nijs RN, Lems WF, Geusens PM, Laan RF, Huisman AM, Algra A, Buskens E, Hofbauer LC, Oostveen AC, Bruyn GA, Dijkmans BA, Bijlsma JW (2007) Prevention of glucocorticoid induced osteoporosis with alendronate or alfacalcidol: relations of change in bone mineral density, bone markers, and calcium homeostasis. J Rheumatol 34:1051-1057
15. Delmas PD, Munoz F, Black DM, Cosman F, Boonen S, Watts NB, Kendler D, Eriksen EF, Mesenbrink PG, Eastell R; HORIZON-PFT Research Group (2009) Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis. J Bone Miner Res 24:1544-1551
16. Burshell AL, Möricke R, Correa-Rotter R, Chen P, Warner MR, Dalsky GP, Taylor KA, Krege JH (2010) Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate. Bone 46:935-939
17. Hochberg MC, Silverman SL, Barr CE, Miller PD (2010) The utility of changes in serum levels of C-terminal telopeptide of type I collagen in predicting patient response to oral monthly ibandronate therapy. J Clin Densitom 13:181-189
18. Blumsohn A, Marin F, Nickelsen T, Brixen K, Sigurdsson G, González de la Vera J, Boonen S, Liu-Léage S, Barker C, Eastell R; EUROFORS Study Group (2011) Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide. Osteoporos Int 22:1935-1946
19. Eastell R, Vrijens B, Cahall DL, Ringe JD, Garnero P, Watts NB (2011) Bone turnover markers and bone mineral density response with risedronate therapy: relationship with fracture risk and patient adherence. J Bone Miner Res 26:1662-1669
20. Eastell R, Christiansen C, Grauer A, Kutilek S, Libanati C, McClung MR, Reid IR, Resch H, Siris E, Uebelhart D, Wang A, Weryha G, Cummings SR (2011) Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res 26:530-537
21. Tsujimoto M, Chen P, Miyauchi A, Sowa H, Krege JH (2011) PINP as an aid for monitoring patients treated with teriparatide. Bone 48:793-803
22. Faulkner KG, Cann CE, Hasegawa BH (1991) Effect of bone distribution on vertebral strength: assessment with patient-specific nonlinear finite element analysis. Radiology 179:669-674
23. Crawford RP, Cann CE, Keaveny TM (2003) Finite element models predict in vitro vertebral body compressive strength better than quantitative computed tomography. Bone 33:744-750
24. Griffith JF, Genant HK (2011) New imaging modalities in bone. Curr Rheumatol Rep 13:241-250
25. Dall'Ara E, Pahr D, Varga P, Kainberger F, Zysset P (2012) QCT-based finite element models predict human vertebral strength in vitro significantly better than simulated DEXA. Osteoporos Int 23:563-572
26. Keaveny TM, Donley DW, Hoffmann PF, Mitlak BH, Glass EV, San Martin JA (2007) Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis. J Bone Miner Res 22:149-157
27. Graeff C, Chevalier Y, Charlebois M, Varga P, Pahr D, Nickelsen TN, Morlock MM, Glüer CC, Zysset PK (2009) Improvements in vertebral body strength under teriparatide treatment assessed in vivo by finite element analysis: results from the EUROFORS study. J Bone Miner Res 24:1672-1680
28. Chevalier Y, Quek E, Borah B, Gross G, Stewart J, Lang T, Zysset P (2010) Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: results from quantitative computed tomography-based finite element analysis of the vertebral body. Bone 46:41-48
29. Keaveny TM, McClung MR, Wan X, Kopperdahl DL, Mitlak BH, Krohn K (2012) Femoral strength in osteoporotic women treated with teriparatide or alendronate. Bone 50:165-170
30. Gluer CC, Marin F, Ringe JD, Hawkins F, Moricke R, Papaioannu N, Farahmand P, Minisola S, Martinez G, Nolla J, Niedhart C, Guanabens N, Nuti R, Martin-Mola E, Thomasius F, Kapetanos G, Pena J, Graeff C, Petto H, Sanz B, Reisinger A, Zysset P (2013) Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the randomized EuroGIOPs trial. J Bone Miner Res. doi: 10.1002/jbmr.1870
31. Canalis E, Mazziotti G, Giustina A, Bilezikian JP (2007) Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 18:1319-1328
32. Hofbauer LC, Rauner M (2009) Minireview: live and let die: molecular effects of glucocorticoids on bone cells. Mol Endocrinol 23:1525-1531
33. Weinstein RS (2010) Glucocorticoids, osteocytes, and skeletal fragility: the role of bone vascularity. Bone 46:564-570
34. Ton FN, Gunawardene SC, Lee H, Neer RM (2005) Effects of low-dose prednisone on bone metabolism. J Bone Miner Res 20:464-470
35. Minisola S, Del Fiacco R, Piemonte S, Iorio M, Mascia ML, Fidanza F, Cipriani C, Raso I, Porfiri ML, Francucci CM, D'Erasmo E, Romagnoli E (2008) Biochemical markers in glucocorticoid-induced osteoporosis. J Endocrinol Invest 31(7 Suppl):28-32
36. Eastell R, Chen P, Saag KG, Burshell AL, Wong M, Warner MR, Krege JH (2010) Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate. Bone 46:929-934
37. Graeff C, Marin F, Petto H, Kayser O, Reisinger A, Pena J, Zysset P, Gluer CC (2013) High resolution quantitative computed tomography-based assessment of trabecular microstructure and strength estimates by finite-element analysis of the spine, but not DXA, reflects vertebral fracture status in men with glucocorticoid-induced osteoporosis. Bone 52:568-577
38. Graeff C, Timm W, Nickelsen TN, Farrerons J, Marín F, Barker C, Glüer CC; EUROFORS High Resolution Computed Tomography Substudy Group (2007) Monitoring teriparatide-associated changes in vertebral microstructure by high-resolution CT in vivo: results from the EUROFORS study. J Bone Miner Res 22:1426-1433
39. Chevalier Y, Charlebois M, Pahra D, Varga P, Heini P, Schneider E, Zysset P (2008) A patient-specific finite element methodology to predict damage accumulation in vertebral bodies under axial compression, sagittal flexion and combined loads. Comput Methods Biomech Biomed Engin 11:477-487
40. Keaveny TM (2010) Biomechanical computed tomography - non-invasive bone strength analysis using clinical computed tomography scans. Ann N Y Acad Sci 1192:57-65
41. Cosman F, Nieves JW, Zion M, Barbuto N, Lindsay R (2008) Effect of prior and ongoing raloxifene therapy on response to PTH and maintenance of BMD after PTH therapy. Osteoporos Int 19:529-535
42. Recker RR, Marin F, Ish-Shalom S, Möricke R, Hawkins F, Kapetanos G, de la Peña MP, Kekow J, Farrerons J, Sanz B, Oertel H, Stepan J (2009) Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis. J Bone Miner Res 24:1358-1368
43. Stepan JJ, Burr DB, Li J, Ma YL, Petto H, Sipos A, Dobnig H, Fahrleitner-Pammer A, Michalska D, Pavo I (2010) Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis. Osteoporos Int 21:2027-2036
44. Cosman F, Keaveny TM, Kopperdahl D, Wermers RA, Wan X, Krohn KD, Krege JH (2012) Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene. J Bone Miner Res. doi: 10.1002/jbmr.1853
45. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD (2003) Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18:1051-1056
46. Bruyère O, Collette J, Rizzoli R, Decock C, Ortolani S, Cormier C, Detilleux J, Reginster JY (2010) Relationship between 3-month changes in biochemical markers of bone remodelling and changes in bone mineral density and fracture incidence in patients treated with strontium ranelate for 3 years. Osteoporos Int 21:1031-1036
47. Melton LJ 3rd, Riggs BL, Keaveny TM, Achenbach SJ, Hoffmann PF, Camp JJ, Rouleau PA, Bouxsein ML, Amin S, Atkinson EJ, Robb RA, Khosla S (2007) Structural determinants of vertebral fracture risk. J Bone Miner Res 22:1885-1892
48. Amin S, Kopperdhal DL, Melton LJ, Achenbach SJ, Therneua TM, Riggs BL, Keaveny TM (2011) Khosla S (2011) Association of hip strength estimates by finite-element analysis with fractures in women and men. J Bone Miner Res 26:1593-1600
49. Keyak JH, Sigurdsson S, Karlsdottir G, Oskarsdottir D, Sigmarsdottir A, Zhao S, Kornak J, Harris TB, Sigurdsson G, Jonsson BY, Siggeirsdottir K, Eiriksdottir G, Gudnason V, Lang TF (2011) Male-female differences in the association between incident hip fracture and proximal femoral strength: a finite element analysis study. Bone 48:1239-1245
50. Sheu Y, Zmuda JM, Boudreau RM, Petit MA, Ensrud KE, Bauer DC, Gordon CL, Orwoll ES, Cauley JA; Osteoporotic Fractures in Men MrOS Research Group (2011) Bone strength measured by peripheral quantitative computed tomography and the risk of nonvertebral fractures: the osteoporotic fractures in men (MrOS) study. J Bone Miner Res 26:63-71
51. Wang X, Sanyal A, Cawthon PM, Palermo L, Jekir M, Christensen J, Ensrud KE, Cummings SR, Orwoll E, Black DM; Osteoporotic Fractures in Men (MrOS) Research Group, Keaveny TM (2012) Prediction of new clinical vertebral fractures in elderly men using finite element analysis of CT scans. J Bone Miner Res 27:808-816
52. Vilayphiou N, Boutroy S, Szulc P, van Rietbergen B, Munoz F, Delmas PD, Chapurlat R (2011) Finite element analysis performed on radius and tibia HR-pQCT images and fragility fractures at all sites in men. J Bone Miner Res 26:965-973
53. Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP (2000) Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 85:3069-3076
54. Orwoll ES, Scheele WH, Pual S, Adami S, Syversen U, Diez-Perez A, Kaufman J-M, Clancy AD, Gaich GA (2003) The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18:9-17
55. Eastell R, Krege JH, Chen P, Glass EV, Reginster JY (2006) Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Curr Med Res Opin 22:61-66
56. Saag KG, Shane E, Boonen S, Marin F, Donley DW, Taylor KA, Dalsky GP, Marcus R (2007) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357:2028-2039
57. Glover SJ, Eastell R, McCloskey EV, Rogers A, Garnero P, Lowery J, Belleli R, Wright TM, John MR (2009) Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. Bone 45:1053-1058